GSK3B and Alzheimer disease: In the Tg2576 AD mouse and aged rat models, chronic bryostatin treatment dramatically reduces the levels of Aβ, recovers the loss of neurotrophic activity and synapses, prevents neuronal apoptosis, inhibits tau phosphorylation by inhibition GSK-3β, and enhances synaptogenesis, leading to recovering cognitive deficits [18], [19].